Biontech Se Stock Return On Equity
| 0A3M Stock | USD 119.15 0.66 0.56% |
BioNTech SE fundamentals help investors to digest information that contributes to BioNTech's financial success or failures. It also enables traders to predict the movement of BioNTech Stock. The fundamental analysis module provides a way to measure BioNTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioNTech stock.
BioNTech |
BioNTech SE Company Return On Equity Analysis
BioNTech's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current BioNTech Return On Equity | 0.24 |
Most of BioNTech's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioNTech SE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, BioNTech SE has a Return On Equity of 0.2382. This is 100.99% lower than that of the Biotechnology sector and 100.65% lower than that of the Health Care industry. The return on equity for all United Kingdom stocks is 176.84% lower than that of the firm.
BioNTech Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioNTech's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioNTech could also be used in its relative valuation, which is a method of valuing BioNTech by comparing valuation metrics of similar companies.BioNTech is currently under evaluation in return on equity category among its peers.
BioNTech Fundamentals
| Return On Equity | 0.24 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.48 % | |||
| Operating Margin | 0.64 % | |||
| Current Valuation | 11.7 B | |||
| Shares Outstanding | 239.77 M | |||
| Shares Owned By Insiders | 65.11 % | |||
| Shares Owned By Institutions | 17.59 % | |||
| Price To Book | 1.39 X | |||
| Price To Sales | 3.48 X | |||
| Revenue | 3.82 B | |||
| Gross Profit | 16.07 B | |||
| EBITDA | 5.94 B | |||
| Net Income | 930.3 M | |||
| Cash And Equivalents | 914.9 M | |||
| Cash Per Share | 3.75 X | |||
| Total Debt | 28.1 M | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 2.67 X | |||
| Book Value Per Share | 83.02 X | |||
| Cash Flow From Operations | 5.37 B | |||
| Earnings Per Share | 18.00 X | |||
| Price To Earnings To Growth | 0.05 X | |||
| Target Price | 219.54 | |||
| Number Of Employees | 5.5 K | |||
| Beta | 0.24 | |||
| Market Capitalization | 31.93 B | |||
| Total Asset | 23.01 B | |||
| Retained Earnings | 19.76 B | |||
| Working Capital | 17.46 B | |||
| Net Asset | 23.01 B |
About BioNTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioNTech SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNTech SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.